Orpyx Medical Technologies Supplies Digital Health Platform for NIH-Funded and Johns Hopkins Medicine-Led Clinical Trial on Diabetic Foot Ulcer Prevention
Summary:** Orpyx Medical Technologies is supplying its Smart Footwear Technology (SFT) platform for an NIH-funded, Johns Hopkins-led Phase 2 trial on DFU prevention in high-risk diabetics. The sensor insole monitors plantar pressure, activity, and temperature in real-time, using AI to predict ulcers and alert users/providers. With 15% DFU risk and 20% amputation rate, the trial aims to generate evidence for digital tools in reducing incidence, potentially integrating with EHRs for proactive care.
Key Highlights:
- SFT Platform: Insole sensors track pressure hotspots, steps, and temp for ulcer prediction.
- Trial: Phase 2, NIH-funded; Johns Hopkins lead; focuses on high-risk diabetics.
- AI Analytics: Alerts for risk; integrates with apps for user education.
- Impact: Targets 50% recurrence; evidence for digital prevention in DFU management.
- Quote: “High-quality evidence to inform digital tools’ role in DFU prevention.”
Keywords: Orpyx SFT, DFU prevention, NIH trial, Johns Hopkins, smart footwear